Joint publication by MD Anderson Cancer Center and Immatics demonstrating the capability of Immatics to validate a new target class, RNA-edited pHLA targets.

Demonstration of Immatics’ capabilities in a collaboration with Genentech to validate neoantigens.

The original paper by Toni Weinschenk, Co-founder and Chief Innovation Officer of Immatics on the XPRESIDENT^® target discovery platform.

Application of the XPRESIDENT^® platform on the therapeutic cancer vaccine IMA901. Development of IMA901 (and of all other cancer vaccines) has been discontinued. However, the paper demonstrates the outstanding capabilities to pioneer biomarker-driven clinical development – as also done in the ongoing Adoptive Cell Therapy (ACT) trials.

Immatics scientists and collaborators present functionally empty and peptide-receptive HLA-A*02:01 molecules that enable quick generation of large libraries of peptide-MHC complexes for TCR screening.

In this commentary, Immatics, peer companies and non-profit institutions evaluate the current regulatory framework around HLA testing for T cell receptor-based therapeutics and propose adjustments that can improve the development of and access to TCR-based therapeutics.

This publication co-authored by the University of Pennsylvania and Immatics highlights Immatics’ differentiated approach utilizing its target and TCR discovery platforms XPRESIDENT® and XCEPTOR® to develop a TCR-based cell therapy approach against COL6A3 exon 6, a novel, proprietary tumor stroma target.

A review by two leaders of Immatics’ Cell Therapy CMC Group.

Description of computational and experimental methods as part of the XPRESIDENT® technology platform that allow identification of true HLA ligands as targets for TCR-based immunotherapies by mass spectrometry.

First publication on the proprietary IMADetect^® target biomarker screening platform by Immatics as used in all ongoing ACT trials. Immatics uses a unique approach setting the qPCR threshold for each target guided by XPRESIDENT^® mass spectrometry.

‍

First publication on the GAPVAC actively personalized vaccine trial conducted by a consortium led by Immatics. The warehouse approach pioneered in GAPVAC was the blueprint for the ongoing ACTolog^® clinical trial by Immatics, which applies the multi-target warehouse approach for the first time in ACT.